Association of Atrial Fibrillation With Incidence of Extracranial Systemic Embolic Events: The ARIC Study.
Mengyuan Shi,Lin Y. Chen,Wobo Bekwelem,Faye L. Norby,Elsayed Z. Soliman,Aniqa B. Alam,Alvaro Alonso
DOI: https://doi.org/10.1161/jaha.120.016724
IF: 6.106
2020-09-02
Journal of the American Heart Association
Abstract:Background Atrial fibrillation (AF) increases the risk of stroke and extracranial systemic embolic events (SEEs), but little is known about the magnitude of the association of AF with SEE. Methods and Results This analysis included 14 941 participants of the ARIC (Atherosclerosis Risk in Communities) study (mean age, 54.2±5.8, 55% women, 74% White) without AF at baseline (1987–1989) followed through 2017. AF was identified from study ECGs, hospital discharges, and death certificates, while SEEs were ascertained from hospital discharges. CHA 2 DS 2 ‐VASc was calculated at the time of AF diagnosis. Cox regression was used to estimate associations of incident AF with SEE risk in the entire cohort, and between CHA 2 DS 2 ‐VASc score and SEE risk in those with AF. Among eligible participants, 3114 participants developed AF and 270 had an SEE (59 events in AF). Incident AF was associated with increased risk of SEE (hazard ratio [HR], 3.58; 95% CI, 2.57–5.00), after adjusting for covariates. The association of incident AF with SEE was stronger in women (HR, 5.26; 95% CI, 3.28–8.44) than in men (HR, 2.68; 95% CI, 1.66–4.32). In those with AF, higher CHA 2 DS 2 ‐VASc score was associated with increased SEE risk (HR per 1‐point increase, 1.24; 95% CI, 1.05–1.47). Conclusions AF is associated with more than a tripling of the risk of SEE, with a stronger association in women than in men. CHA 2 DS 2 ‐VASc is associated with SEE risk in AF patients, highlighting the value of the score to predict adverse outcomes and guide treatment decisions in people with AF. Nonstandard Abbreviations and Acronyms AF atrial fibrillation ARIC Atherosclerosis Risk in Communities HR hazard ratio ICD International Classification of Diseases ICD‐9-CM International Classification of Diseases, Ninth Revision, Clinical Modification SEE systemic embolic event Clinical Perspective What Is New? This study estimates for the first time in a community‐based cohort the association of incident atrial fibrillation (AF) with the risk of extracranial systemic embolic events, with AF patients having a 3.6 times higher risk of systemic embolic events. The association between AF and systemic embolic events was stronger in women than men. A higher CHA 2 DS 2 ‐VASc score was associated with higher risk of systemic embolic events among patients with AF. What Are the Clinical Implications? This study complements the existing knowledge about the adverse outcomes associated with AF and further supports the use of CHA 2 DS 2 ‐VASc as a predictive tool in patients with AF. Atrial Fibrillation (AF) affects an estimated 33.5 million patients worldwide and is associated with increased risk of stroke, mortality, and morbidity, accompanied by higher healthcare burden. 1 , 2 Cardioembolic stroke is one of the most important complications of AF, leading to substantial disability and mortality in these patients. 3 Oral anticoagulation has demonstrated consistent effectiveness in the prevention of cardioembolic stroke among AF patients. 4 The same mechanisms that lead to elevated risk of ischemic stroke in AF are also likely to increase risk of extracranial systemic embolic events (SEEs). 5 A pooled analysis of recent clinical trials of anticoagulation in AF showed that 1 in 9 thromboembolic events in AF patients were SEEs. 6 Although there is extensive epidemiologic evidence of increased risk of ischemic stroke among individuals with AF, 7 , <a class=" -Abstract Truncated-
cardiac & cardiovascular systems